Androgen receptor (AR) is a member of the nuclear receptor superfamily which acts as a ligand-dependent transcription factor (Beato, M., Herrlich, P., Schütz, 1989 Metab. 8,. There are indications that AR may also have other functions. For example, structural alterations of the AR sequence have been implicated in prostate cancer (Visakorpi, T., Huytinen, E., Koivisto, P., Tanner, M., Keinänen, R., Palmberg, C., Palotie, A., Tammela, T., Isola, J., Kallioniemi, O.-P., 1995. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nature Genet. 9, 401-406.) and in the development of spinal and bulbar muscular atrophy, a neurodegenerative disease (Kennedy, W.R., Alter, M., Sung, J.H., 1968. Progressive proximal spinal and bulbar muscular atrophy of late onset: a sex-linked recessive trait. Neurology 18,[671][672][673][674][675][676][677][678][679][680]. Here, we have investigated the spatial and temporal expression of AR during mouse organogenesis by in situ hybridisation. We demonstrate that AR transcripts occur in the developing external genitalia, pituitary, adrenals, kidneys and musculus levator ani, in addition to the known expression sites in the Wolffian ducts and its derivatives and during development of the mammary glands.
A number of studies have implicated androgen receptor (AR) in sexual development. They mostly assessed localisation of AR protein by immunohistochemistry and binding of radioactive ligands (Chang et al., 1995; Bagatell and Bremner, 1996) . Two reports described AR mRNA localisation in the adult and developing mouse prostate by using a heterologous rat cDNA as in situ probe . Here we report for the first time a systematic analysis of AR mRNA expression during mouse embryogenesis using a probe specific for mouse AR (see Section 1). This study was performed (i) to identify new expression sites (ii) to detect the earliest expression patterns using a sensitive technique and (iii) to provide a reference point for analysing a potential physiological role for cofactors of AR such as ARA70 (Yeh and Chang, 1996) . AR mRNA expression was detected from E12.5 onwards, shortly before embryonic hormone production starts, at about E13 (Ikeda et al., 1994) . During development of the external genitals, AR expression was found in the genital tubercle in both sexes (Fig. 1A and data not shown). As it elongates into the phallus, AR signals were found in the labioscrotal and urethral folds, which develop into scrotum (male) and labia majora (female), and ventral aspect of penis (male) and labia minora (female), respectively (Fig.  1B,C) .
In the mesonephric mesenchyme AR mRNA was detected at E12.5 in both sexes ( Fig. 1D and shown) and continued to be expressed in the mesonephric mesenchyme around the differentiating ductal system ( Fig.  1E-I ). In males the mesonephric (Wolffian) duct develops in a cranio-caudal fashion into epididymis, seminal vesicles, vas deferens and ejaculatory duct (Cunha and Lung, 1979; Cooke et al., 1991) . A gradual shift of AR expression from (E,H,I ) Transverse sections. b, neck of bladder; bl, bladder; cc, crus clitoridis; cp, crus penis; E, embryonic day p.c.; e, epididymis; eb, epithelial buds of future prostate; f, female; gt, genital tubercle; lf, labioscrotal folds; M, Müllerian duct; m, male; mes, mesonephros; met, metanephros; pu, prostatic region of urethra; s, duct of seminal vesicle; st, seminiferous tubules; t, testis; u, urethra; uf, urethral folds; us, urogenital sinus; W, Wolffian duct. mesenchyme to ductal epithelia was observed during this process, starting at about E15.5 (Fig. 1G,I and data not shown).
The embryo depicted in Fig. 1I , for example, showed expression in both mesenchyme and epithelia of seminal vesicles and vas deferens, whereas the signal in Fig. 1G was mainly confined to the epithelia of the epididymal ducts. Epithelial buds, from which a functional prostate develops after birth (Cunha, 1994) , were negative during embryogenesis (Fig. 1I ), in agreement with detection of AR protein (Shannon and Cunha, 1983; , but in contrast to a study that was using rat AR cDNA as in situ probe . In the absence of androgen-mediated mesenchymal-epithelial interactions the Wolffian ducts degenerate in females (Cunha et al., 1980) , where expression of AR was restricted to mesenchymal tissue around the paramesonephric (Müllerian) ducts, from the bladder to its caudal end, excluding a segment at the dorsalmost aspect (asterisk in Fig. 1H') . The mesenchyme around the differentiating urogenital sinus was positive in both sexes (Fig. 1A,B,H,I ).
During mammary development, AR was expressed in male and female embryos from E12.5 to E14.5 in the mesenchyme surrounding the epithelial gland ( Fig. 2A,B and data not shown). Expression continued in females until E18.5 (Fig. 2D,F) , whereas it ceased in males concomitant with the degeneration of the gland, starting at E14.5 (Fig. 2C,E) . This expression pattern is in line with tissue recombination experiments which showed that mesenchymal cells are the target for androgen-induced arrest of mammary development (Kratochwil and Schwartz, 1976; Dürnberger and Kratochwil, 1980) .
Further sites of AR expression during development were found in the glandular part of the pituitary (Fig. 2G) , the adrenal gland (Fig. 2H) , and in the musculus levator ani (Fig. 2I) , a muscle of the external genitals which initiates in the pelvic region between the pubic and ischial bone (not shown). Minor sites of expression were found in the testis (Fig. 1E,G) , kidney (Fig. 2H) , hypothalamus, dorsal root ganglia and larynx (not shown).
Methods

In situ hybridisation
The sex of embryos was determined by PCR of embryonic tail DNA for Sry and Zfy as described (Hogan et al., 1994) . A 1665-bp EcoRI-HindIII restriction fragment of mouse AR cDNA (Faber et al., 1991) , which contains the N-terminal region of the receptor, was subcloned into pBluescript (Stratagene) and used for in vitro transcription of antisense and sense control 35 S-labelled RNA probes. Hybridisation to histological sections and detection was performed according to standard protocols (Hogan et al., 1994) .
